SemaglutideGLP-1 PeptideSafety Rating 8/10
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Save ~99% vs Wegovy LillyDirect
Research-grade Semaglutide is for laboratory and research use only, not approved for human consumption. Always consult a licensed physician before working with any compound. Ozempic FDA-approved 2017 for type 2 diabetes; Wegovy 2021 for weight loss. Insurance coverage varies; cash-pay retail consistently around $1,000/mo for non-covered patients.
See all Semaglutide vendors →Price Comparison
Compare vendors · per 5mg
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| Red River PeptidesBest $/mgCOA ✓ · 3PAvailable on backorder | $25.50 | $1.27 | May 19, 2026 | Buy → |
| Red River PeptidesCOA ✓ · 3PAvailable on backorder | $17.00 | $1.70 | May 19, 2026 | Buy → |
| Optimum FormulaCOA ✓ · 3P | $157.49 | $5.25 | May 14, 2026 | Buy → |
| PeptiraCOA ✓ · 3P | $119.00 | $5.95 | May 14, 2026 | Buy → |
| Chameleon PeptidesCOA ✓ · 3P | $69.30 | $6.93 | Apr 17, 2026 | Buy → |
Overview
About Semaglutide
Mechanism of action
GLP-1 receptor agonist. Stimulates insulin secretion, inhibits glucagon, slows gastric emptying, reduces appetite via hypothalamic signaling.
Safety profile
Nausea, vomiting, diarrhea, constipation, pancreatitis risk, gallbladder disease, thyroid C-cell tumor risk (theoretical), injection site reactions. · Extensive safety data; GI side effects common but manageable; cardiovascular benefit; thyroid warning animal-only
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Semaglutide below your target.
Safety & Interactions
Contraindications & Drug Interactions
Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.
Personal or family history of medullary thyroid carcinoma (MTC). FDA black-box warning.
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Prior serious hypersensitivity reaction to semaglutide or any excipient.
Related pages
More on Semaglutide
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- The STEP 1 Phase 3 trial (NEJM 2021) showed once-weekly semaglutide 2.4 mg produced a mean 14.9% body weight reduction vs 2.4% with placebo over 68 weeks in adults with obesity — with 86.4% of participants achieving ≥5% weight loss and over half achieving ≥15%.
- The SELECT cardiovascular outcomes trial (NEJM 2023, n=17,604) demonstrated a 20% reduction in major adverse cardiovascular events (HR 0.80) in overweight/obese patients without diabetes who had pre-existing cardiovascular disease — the first anti-obesity drug to show MACE reduction and prompting a new FDA indication.